Labat AfricaJSE:LAB ROC (Joel Greenblatt) % is 70.00% as of Nov. 2025. The stock has 5 warning signs investors should review. Among 978 Drug Manufacturers companies, Labat Africa ranks better than 94.07% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Labat Africa's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2025 was 70.00%.
The historical rank and industry rank for Labat Africa's ROC (Joel Greenblatt) % or its related term are showing as below:
JSE:LAB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -594.96 Med: -60.6 Max: 3297.67
Current: 111.74
During the past 13 years, Labat Africa's highest ROC (Joel Greenblatt) % was 3297.67%. The lowest was -594.96%. And the median was -60.60%.
JSE:LAB's ROC (Joel Greenblatt) % is ranked better than 94.07% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.32
vs JSE:LAB: 111.74
Labat Africa's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Labat Africa (JSE:LAB) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Labat Africa ROC (Joel Greenblatt) % Related Terms
Labat Africa ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Labat Africa's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:LAB vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Labat Africa's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Nov. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 70.00% mean?
Labat Africa (JSE:LAB) has a ROC (Joel Greenblatt) % of 70.00% as of Nov. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Labat Africa and its competitors. According to the industry distribution chart, Labat Africa ranks #58 out of 978 companies in the Drug Manufacturers industry, placing it in the top 5.9%.
Is Labat Africa's ROC (Joel Greenblatt) % too high?
Labat Africa's current ROC (Joel Greenblatt) % is 70.00%. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.32. Labat Africa's value of 70.00% is 518.4% above this industry median. Based on the distribution chart, Labat Africa ranks #58 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Labat Africa's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #58 out of 978 companies for ROC (Joel Greenblatt) %. This places Labat Africa in the top 6% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.32. Labat Africa's value of 70.00% is 518.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.32, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current ROC (Joel Greenblatt) % of 70.00% is 518.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Labat Africa and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current ROC (Joel Greenblatt) % is 70.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.22, compared to a current price of R0.05 — trading 77.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 70.00% and 518.4% above the Drug Manufacturers industry median of 11.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current ROC (Joel Greenblatt) % is 70.00% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 